WOBURN, MA / ACCESSWIRE / March 27, 2023 / Biofrontera Inc. (NASDAQ:BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that it is executing on the company's stated plans to invest in and meaningfully grow its' salesforce in 2023.
"With this investment in the salesforce, Biofrontera is taking an important step forward in our growth strategy," stated Erica Monaco, Chief Executive Officer of Biofrontera Inc. "The success of our FDA-approved therapy for actinic keratosis (AK), Ameluz-PDT, is directly related to our ability to educate dermatologists and patients about AK and the potential health benefits of our therapy. The strengthening of our sales effort will greatly improve our reach in key dermatology markets across the United States and position us well to further penetrate this large opportunity."
"We achieved record revenues and grew market share in 2022 with fewer sales people and territories than we had pre-COVID - an example of the capabilities of our current team," continued Ms. Monaco. "Today, we are adding a new sales region and growing the salesforce by almost 30% to now cover 40 territories. We are also adding a combined 140 years of healthcare and dermatology experience to our existing customer coverage. Biofrontera is at an important, business inflection point and we are confident that this expansion of the salesforce will enable us to accelerate growth and continue our market share gains in 2023 and beyond."
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit http://www.biofrontera-us.com.
Forward-looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, as amended to date. These statements include, but are not limited to, statements relating to the growth strategy for Biofrontera Inc.'s (the "Company") Ameluz-PDT, improved market opportunities, educational outreach efforts, growth of the Company's salesforce and its sales territories and the impact of expanding the Company's salesforce on growth. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless, actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking statements we make. These risks and uncertainties, many of which are beyond our control, including, but not limited to, the impact of any extraordinary external events; any changes in the Company's relationship with its licensors; the ability of the Company's licensors to fulfill their obligations to the Company in a timely manner; the Company's ability to achieve and sustain profitability; whether the current global disruptions in supply chains will impact the Company's ability to obtain and distribute its licensed products; changes in the practices of healthcare providers, including any changes to the coverage, reimbursement and pricing for procedures using the Company's licensed products; the uncertainties inherent in the initiation and conduct of clinical trials; availability and timing of data from clinical trials; whether results of earlier clinical trials or trials of Ameluz in combination with BF-RhodoLED in different disease indications or product applications will be indicative of the results of ongoing or future trials; uncertainties associated with regulatory review of clinical trials and applications for marketing approvals; whether the market opportunity for Ameluz in combination with BF-RhodoLED is consistent with the Company's expectations; the Company's ability to comply with public company requirements; the Company's ability to regain compliance with Nasdaq continued listing standards, the Company's ability to retain and hire key personnel; the sufficiency of cash resources and need for additional financing and other factors that may be disclosed in the Company's filings with the SEC, which can be obtained on the SEC website at http://www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date on which they are made and reflect management's current estimates, projections, expectations and beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.
Contact:
Biofrontera Investor Relationsir@bfinc.com
SOURCE: Biofrontera Inc.
View source version on accesswire.com:https://www.accesswire.com/745901/Biofrontera-Inc-Makes-Transformative-Investment-in-Its-Dermatology-Salesforce
See the article here:
Biofrontera Inc. Makes Transformative Investment in Its' Dermatology ... - BioSpace
- Top 5 Dermatology Articles of 2024 - Managed Healthcare Executive - January 1st, 2025 [January 1st, 2025]
- DEI programs, sun safety: Read this years top practice management articles in dermatology - Healio - January 1st, 2025 [January 1st, 2025]
- Cutaneous Connection 2024: Top Dermatology Podcast Episodes and Insights of the Year - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Top Insights and Highlights from Dermatology Times' Interview Intersection: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Providing Support for Comorbidities and Psychological Health in Patients with Atopic Dermatitis - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Reviewing Major Dermatologic Studies of the Year: 2024 - Dermatology Times - January 1st, 2025 [January 1st, 2025]
- Peak Dermatology in Visalia hopes to provide more skin services and treatment to the area - KFSN-TV - December 23rd, 2024 [December 23rd, 2024]
- Krystal Tawney of Pinnacle Dermatology celebrates 10 years of business in the Greenbrier Valley - Real WV - December 23rd, 2024 [December 23rd, 2024]
- Supporting Pediatric Patients With AD and Their Caregivers - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Photodynamic Therapy is an Effective, Long-Term Treatment for Actinic Keratosis - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times - December 23rd, 2024 [December 23rd, 2024]
- Advanced Dermatology to pay $15G fine after doctor refused to perform procedure on HIV-infected patient - Newsday - December 9th, 2024 [December 9th, 2024]
- Efficacy of Combining Postbiotic Formulation with Microneedling for Acne - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Burden of Hidradenitis Suppurativa on Patients and Diagnostic Challenges - Dermatology Times - December 9th, 2024 [December 9th, 2024]
- Opioid-Prescribing Trends in Dermatology From 2014 to 2020 in the United States - Cureus - November 28th, 2024 [November 28th, 2024]
- Amid challenges, the Baton Rouge dermatology industry is evolving - Greater Baton Rouge Business Report - November 28th, 2024 [November 28th, 2024]
- Polynucleotide Therapy Shows Promise in Scar and Burn Management - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Revolutionizing Dermatology: How Emerging Technologies are Shaping the Future of Skin Care - Spherical Insights - November 28th, 2024 [November 28th, 2024]
- Dermatology OTC Medications Market Size, Scope Analysis, Key Insights, Leading Key Players, And Forecast To 2033 - openPR - November 28th, 2024 [November 28th, 2024]
- Jeff Stark, MD: Insights on the Approval of Bimekizumab for HS - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Exploring the Atopic Dermatitis Treatment Paradigm and Challenging Cases: Part 2 - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- Patient Education and Novel Topical Therapies for AD - Dermatology Times - November 28th, 2024 [November 28th, 2024]
- TikTok dermfluencers have medical students flocking to dermatology, where they can make half a million dollars a year and work four days a week -... - November 20th, 2024 [November 20th, 2024]
- $500,000 Pay, Predictable Hours: How Dermatology Became the It Job in Medicine - The Wall Street Journal - November 20th, 2024 [November 20th, 2024]
- Empowering Dermatology PAs Through Education and Career Support - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- U.S. Dermatology Partners Announces the Opening of Stephenville, Texas Office - PR Web - November 20th, 2024 [November 20th, 2024]
- $500,000 Pay, Predictable Hours: How Dermatology Became the It Job in Medicine - Yahoo! Voices - November 20th, 2024 [November 20th, 2024]
- FRONTIER-2 Study Evaluates Safety and Efficacy of Tozorakimab in Patients with AD - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- Improving Care and Innovations in Vitiligo and Atopic Dermatitis: Part 1 - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- In the United States, the dermatology concentration of doctors is also noticeable.The Wall Street Jo.. - - November 20th, 2024 [November 20th, 2024]
- Dermatology Diagnostic Devices and Therapeutics Market Size, Trends and Industry Growth Forecast to 2032 - openPR - November 20th, 2024 [November 20th, 2024]
- POLL: What Topics Are You Looking Forward to at SDPA Fall 2024? - Dermatology Times - November 20th, 2024 [November 20th, 2024]
- Digital tool aims to tackle long dermatology waits - Health and Care News Scotland - November 20th, 2024 [November 20th, 2024]
- Is AI Coming for My Job?: Familiarizing Clinicians with AI Tools and Their Role in Dermatology - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- Almiralls Nine-Month 2024 Results: Almirall Reports Strong Performance at Q3 2024 - Driven by Successful Commercial Execution of the Dermatology... - November 12th, 2024 [November 12th, 2024]
- Updates on the Latest Cosmetic Treatments in Medical Care - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- Jenny Murase, MD: Emerging Therapies Bring Hope to Patients with Persistent Itch - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- POLL: Are You Attending the Elevate-Derm West Conference? - Dermatology Times - November 12th, 2024 [November 12th, 2024]
- Memorial Health System is re-opening of Department of Dermatology - Parkersburg News - October 26th, 2024 [October 26th, 2024]
- Available Therapeutics and Upcoming Advancements in Atopic Dermatitis and Prurigo Nodularis - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Sun Pharma Announces Multiple Data Presentations Highlighting its Dermatology Portfolio to be Featured at the 2024 Fall Clinical Dermatology... - October 26th, 2024 [October 26th, 2024]
- What To Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD - MD Magazine - October 26th, 2024 [October 26th, 2024]
- Navigating Complexities and Unmet Needs of Chronic Hand Eczema - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Schweiger Dermatology Group Expands in Florida with the Acquisition of ClearlyDerm, Adding 5 New Offices in South Florida - PR Newswire - October 26th, 2024 [October 26th, 2024]
- Leo Pharma tells doctors to 'Talk to the Hand' in new dermatology campaign - FiercePharma - October 26th, 2024 [October 26th, 2024]
- Dermatology Partners To Expand Maryland Presence With New Westminster Clinic, Hosts Free Skin Cancer Screenings For Veterans On November 11 - citybiz - October 26th, 2024 [October 26th, 2024]
- Peter Lio, MD: The Latest Perspectives on Pathophysiology and Treatment of Eczema - Dermatology Times - October 26th, 2024 [October 26th, 2024]
- Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell... - October 26th, 2024 [October 26th, 2024]
- Dermatology Patients Taking Biologics are Wary About Most Vaccines - Medpage Today - October 13th, 2024 [October 13th, 2024]
- Safe and Effective: Upadacitinib Shows Promise in PN Treatment - Dermatology Times - October 13th, 2024 [October 13th, 2024]
- SPONSORED: First Care, Heartland Dermatology team up again for free health screening event - Hays Post - October 13th, 2024 [October 13th, 2024]
- Global Dermatology Drugs Market to Worth Over US$ 50.42 Billion By 2032 | Astute Analytica - GlobeNewswire - October 13th, 2024 [October 13th, 2024]
- Working to Improve Mental Health - Dermatology Times - October 13th, 2024 [October 13th, 2024]
- Bimekizumab Demonstrates Safety and Efficacy in Elderly Patients with Psoriasis - Dermatology Times - October 13th, 2024 [October 13th, 2024]
- Analyzing Efficacy and Safety in Diverse Clinical Trials: New Roflumilast Data - Dermatology Times - October 2nd, 2024 [October 2nd, 2024]
- UCB at EADV 2024: committed to advancing care in immuno-dermatology - UCB - October 2nd, 2024 [October 2nd, 2024]
- Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations - Dermatology Times - October 2nd, 2024 [October 2nd, 2024]
- Expert Insights Into Handling Treatment Challenges and Site-Specific Concerns in Vitiligo Management - Dermatology Times - October 2nd, 2024 [October 2nd, 2024]
- Dermatology Excimer Laser Market is expected to Double Its Size - openPR - October 2nd, 2024 [October 2nd, 2024]
- InflaRx Presents Post Hoc Analysis of SHINE Trial of Vilobelimab in Hidradenitis Suppurativa at the 2024 European Academy of Dermatology and... - October 2nd, 2024 [October 2nd, 2024]
- Discussing Unmet Needs Among Patients in Dermatology, with Matthew Zirwas, MD - MD Magazine - September 23rd, 2024 [September 23rd, 2024]
- Organon Moves Into Branded Dermatology With Dermavant Takeout - Scrip - September 23rd, 2024 [September 23rd, 2024]
- Dermatology Research Team Investigating the Most Common Disease Youve Never Heard About - University of Miami - September 23rd, 2024 [September 23rd, 2024]
- Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress - Business Wire - September 23rd, 2024 [September 23rd, 2024]
- Hensin Tsao, MD, PhD: TIL Therapy and Neoadjuvant Treatment for Pigmented Lesions - Dermatology Times - September 23rd, 2024 [September 23rd, 2024]
- Derm In The News: September 8-14 - Dermatology Times - September 15th, 2024 [September 15th, 2024]
- April Armstrong, MD, MPH, Shares Insights on the NPF's Psoriasis Health Indicator Report - Dermatology Times - September 15th, 2024 [September 15th, 2024]
- Nearly half of FDA-authorized AI tools may be ineffective - Dermatology Times - September 15th, 2024 [September 15th, 2024]
- Dermatology Diagnostic Devices And Therapeutics Market - openPR - September 15th, 2024 [September 15th, 2024]
- Industry Deep Dive: Dermatology Devices Market Size, Share, and Growth Forecast with Emerging Trends through 2032 - openPR - September 15th, 2024 [September 15th, 2024]
- SPROUT Trial Highlights Benefits of Apremilast for Pediatric Psoriasis - Dermatology Times - September 15th, 2024 [September 15th, 2024]
- Veterinary Dermatology Drugs Market Global Latest Trends and Insights 2024 to 2031 - openPR - September 15th, 2024 [September 15th, 2024]
- Championing equity in skin of color dermatology - Fierce healthcare - August 5th, 2024 [August 5th, 2024]
- Derm In The News: July 28-August 3 - Dermatology Times - August 5th, 2024 [August 5th, 2024]
- Interview Intersection: Expert Interviews From July 2024 - Dermatology Times - August 5th, 2024 [August 5th, 2024]
- Generation Z, Millennials Exhibit Similar Subjective Perception of Atopic Dermatitis Disease Severity - Dermatology Times - August 5th, 2024 [August 5th, 2024]
- Long-Term Efficacy and Insights from POETYK PSO-1 Studies: Implications for Psoriasis Treatment - Dermatology Times - August 5th, 2024 [August 5th, 2024]
- Laurel Dermatology emphasizes the importance of sunscreen - WDAM - July 26th, 2024 [July 26th, 2024]
- The Interplay Between Sleep Disorders and Dermatology - Dermatology Times - July 26th, 2024 [July 26th, 2024]
- Latex Gloves and the Americans With Disabilities Act - Dermatology Times - July 26th, 2024 [July 26th, 2024]